Loading…
German maker of branded generic drugs, specialty pharmaceuticals and OTC health products, also producing allergy immunotherapies.
German maker of branded generic drugs, specialty pharmaceuticals and OTC health products, also producing allergy immunotherapies.
Grows largely by buying established brand-name drugs and making them in its own German plants, so it earns manufacturing margin on mature products rather than depending on new launches. The founding Beier family remains the controlling shareholder. It also filled COVID vaccine doses under contract for BioNTech.
In one line: A German branded-generics maker like a smaller Perrigo/Amneal.
Moat: narrow (brand, regulatory licence, scale). Established branded-generic portfolio and German manufacturing base, but generics pricing is competitive.
Headquarters: Grafelfing, Germany · Founded: 1991 · Employees: 3,500
Size Dermapharm (DMP.DE) is a Germany Health Care company (Pharmaceuticals: Major) with a market value of $2.11B, the 105th largest of 205 Germany companies the cockpit tracks. Shares closed at €38.00 on 6 Nov 2026.
Performance Over six months the shares fell 24.8%, against -6.3% for the median peer and +2.6% for the Germany market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 0.4% over the last twelve months (peer median -1.3%); the operating margin is 22.2% (peer median 9.7%).
Valuation It trades at 14.5× forward earnings against a peer median of 19.3× (7th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.2 points above its cost of capital (6.0% WACC).
Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €1.18B | €1.16B | €1.18B | €1.14B | €1.02B |
| Revenue growth | — | -1% | +4% | +11% | — |
| Gross profit | €410M | €392M | €390M | €343M | €370M |
| EBITDA | €358M | €314M | €298M | €305M | €362M |
| Net income | €147M | €132M | €114M | €62.4M | €134M |
| Free cash flow | €171M | €139M | €114M | €150M | €247M |
| Capital expenditure | €48.4M | €42.1M | €38.2M | €41.5M | €39.0M |
| Total debt | €1.17B | €1.05B | €980M | €1.08B | €516M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Dermapharm DMP.DE | $2.11B | -25% | 0% | 22% | 14.5× | -3.8% |
| Sandoz SDZ.SW | $44.4B | +24% | +1% | 15% | 25.3× | 7.9% |
| Perrigo PRGO | $2.20B | +35% | -4% | 5% | 6.3× | 13.1% |
| Viatris VTRS | $22.9B | +17% | +5% | 10% | 7.5× | 12.5% |
| Hikma Pharmaceuticals HIK.L | $4.59B | +18% | +2% | 20% | 9.9× | 1.4% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.7B | +19% | -4% | 19% | 15.1× | 10.2% |
| ALK-abello A/S ALK-B.CO | $8.14B | -5% | +17% | 27% | 35.7× | 7.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DMP.DE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.4% | -1.0% | 10th highest of 21 |
| 6-month return | -24.8% | -6.3% | 7th lowest of 21 |
| Distance from 52-week high | -26.8% | -32.7% | 8th highest of 21 |
| Revenue growth (TTM) | +0.4% | -1.3% | 10th highest of 20 |
| Operating margin | 22.2% | 9.7% | 5th highest of 20 |
| Forward P/E | 14.5× | 19.3× | 7th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -3.8% | 9.1% | 2nd least demanding of 18 |
| Growth delivered (Del g) | +8.0% | +6.5% | 8th highest of 18 |
| Hurdle (Req g minus delivered) | -11.7 pp | -0.2 pp | 5th least demanding of 18 |
| ROIC minus cost of capital | +6.2 pp | -2.8 pp | 3rd highest of 20 |
| EV / EBITDA | 8.0× | 11.1× | 2nd cheapest of 7 |
| Net debt / EBITDA | 2.7× | 1.3× | 3rd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Dermapharm DMP.DE | Germany | $2.11B | -25% | 0% | 22% | 14.5× | -3.8% | +8.0% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.12B | +17% | -1% | 14% | 17.5× | 2.4% | +15.7% |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $2.12B | -41% | -18% | 9% | n/a | 37.9% | +0.9% |
| Zymeworks ZYME | United States | $2.10B | +24% | -70% | -419% | 12.0× | n/a | n/a |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $2.13B | -27% | +5% | -18% | n/a | n/a | n/a |
| Harbin Pharmaceutical 600664.SS | China | $2.10B | +55% | +2% | 5% | 23.1× | -2.9% | +8.2% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.15B | -3% | +9% | 14% | 22.8× | 6.1% | +6.4% |
| Jinyu Bio-Technology 600201.SS | China | $2.04B | -15% | +22% | 10% | 62.4× | 24.4% | -2.4% |
| Haw Par H02.SI | Singapore | $2.18B | -27% | -13% | 30% | 12.4× | 3.7% | +15.7% |
| Biohaven BHVN | United States | $2.19B | +47% | n/a | n/a | n/a | n/a | n/a |
| Prestige Consumer Healthcare PBH | United States | $2.04B | -18% | -1% | 26% | 9.3× | -0.2% | +2.9% |
| Perrigo PRGO | United States | $2.20B | +35% | -4% | 5% | 6.3× | 13.1% | +0.8% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.02B | +7% | +5% | 22% | 15.9× | -4.8% | +10.6% |
| Qingdao Baheal Medical 301015.SZ | China | $2.02B | +4% | -6% | 8% | 23.5× | 11.9% | +5.0% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $2.01B | -27% | +7% | 13% | 9.8× | 1.2% | +14.1% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.01B | +24% | +20% | 12% | 24.4× | 25.0% | +6.5% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $2.01B | -9% | -9% | 30% | 19.3× | 9.1% | +9.3% |
| BrightGene Bio-Medical Technology 688166.SS | China | $2.00B | -51% | +14% | 7% | 87.6× | 38.5% | +9.2% |
| United Laboratories International 3933.HK | Hong Kong | $2.00B | -19% | -13% | 5% | 14.5× | 3.7% | +7.8% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.99B | -28% | -28% | -50% | 25.7× | 14.0% | -11.0% |
| Sino Biological 301047.SZ | China | $1.98B | +50% | +20% | 17% | 63.8× | 36.8% | -15.1% |